Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer
Open Access
- 1 March 2021
- journal article
- research article
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 506-521
Abstract
The renin-angiotensin system (RAS) is up-regulated in patients with colorectal cancer (CRC) and is reported to be associated with poor prognosis and chemo-resistance. Here we explored the therapeutic potential of targeting RAS in CRC using Losartan, an angiotensin receptor blocker. An integrative-systems biology approach was used to explore a proteome-level dataset of a gene signature that is modulated by Losartan. The anti-proliferative activity of Losartan was evaluated using 2- and 3-dimensional cell culture models. A xenograft model of colon cancer was used to investigate tumor growth with Losartan alone and in combination with 5-FU followed by histological staining (Hematoxylin & Eosin and Masson trichrome staining), biochemical analyses, gene expression analyses by RT-PCR, western blot/IHC, or MMP Gelatin Zymography studies. Effects on cell cycle and cell death were assessed by flow cytometry. Losartan inhibited cell growth and suppressed cell cycle progression, causing an increase in CRC cells in the G1 phase. Losartan significantly reduced tumor growth and enhanced tumor cell necrosis. An impact on the inflammatory response, including up-regulation of pro-inflammatory cytokines and chemokines in CRC cells are potential mechanisms that could partially explain Losartan’s anti-proliferative effects. Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited matrix metalloproteinase-2 and -9 activities and decreased tumor vasculature. These data demonstrate the therapeutic potential of combining chemotherapeutic regimens with Losartan to synergistically enhance its activity and target the renin-angiotensin system as a new approach in colorectal cancer treatment.Keywords
This publication has 48 references indexed in Scilit:
- BRG1 Is a Prognostic Marker and Potential Therapeutic Target in Human Breast CancerPLOS ONE, 2013
- The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancerBreast Cancer Research, 2013
- Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signalingOncology Reports, 2012
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding MetastasesClinical Cancer Research, 2010
- Angiotensin type 2 receptor–mediated apoptosis of human prostate cancer cellsMolecular Cancer Therapeutics, 2009
- Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk FactorsClinics in Colon and Rectal Surgery, 2009
- Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal DisseminationClinical Cancer Research, 2005
- G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cellsAmerican Journal of Physiology-Cell Physiology, 2004
- Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death MachineryCell, 1997
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971